Galectin Therapeutics 发布FDA书面回复后的监管更新,并宣布Richard E. Uihlein提供额外1000万美元的信用额度,足以覆盖至2027年3月的预期支出
Galectin Therapeutics 发布FDA书面回复后的监管更新,并宣布Richard E. Uihlein提供额外1000万美元的信用额度,足以覆盖至2027年3月的预期支出
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.